Clinical Trial: A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomized, Double Blind, Placebo-controlled Phase II Study of KPS-0373 in Patients With SCD
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of KPS-0373 compared to placebo in patients with Spinocerebellar Degeneration (SCD).
Detailed Summary:
Sponsor: Kissei Pharmaceutical Co., Ltd.
Current Primary Outcome: Change from baseline in Scale for the assessment and rating of ataxia (SARA) [ Time Frame: 24 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Change from baseline in patient improvement impression of activities of daily living [ Time Frame: 24 weeks ]
Original Secondary Outcome: Change from baseline in patient improvement impression of ADL [ Time Frame: 24 weeks ]
Information By: Kissei Pharmaceutical Co., Ltd.
Dates:
Date Received: June 23, 2011
Date Started:
Date Completion:
Last Updated: November 29, 2012
Last Verified: March 2012